RxDoctor Payments Data

Nisha Lakhani, MD

Internal Medicine · Nyack, NYNPI 1336158609

Payments from drug & device makers

$7,494in general payments, 2019–2025

Across 440 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$868
  • Novo Nordisk$694
  • Boehringer Ingelheim$644
  • Lilly USA, LLC$535
  • GSK$505
  • plus $3K from 29 others

What the payments were for

  • Food & beverage$7,44499%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,494 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$115,832
Medicare patients
381
Services billed
1,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$196,384
JanuviaSitagliptin Phosphate55$62,547
Synjardy XrEmpagliflozin/Metformin Hcl35$58,668
FarxigaDapagliflozin Propanediol44$50,530
EliquisApixaban28$40,166
JardianceEmpagliflozin23$33,121
ProliaDenosumab19$32,514
Xigduo XrDapaglifloz Propaned/Metformin18$29,269
Repatha SureclickEvolocumab21$24,700
Janumet XrSitagliptin Phos/Metformin Hcl12$19,898
Praluent PenAlirocumab19$15,967
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$11,343
Breo ElliptaFluticasone/Vilanterol13$9,430
Rosuvastatin Calcium374$4,611
Levothyroxine Sodium322$4,107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$694$196,384107 claims
Boehringer IngelheimSynjardy Xr, Jardiance$644$91,78858 claims
MerckJanuvia, Janumet Xr$130$82,44467 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,250$61,87358 claims
PfizerEliquis, Paxlovid$402$42,96344 claims
AmgenProlia$227$32,51419 claims
GSKBreo Ellipta$505$9,43013 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$13$4,107322 claims
AbbVieSynthroid$868$3,10559 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Nyack

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →